IMITREX 6 MG / 0.5 ML
SUMATRIPTAN (SUMATRIPTAN SUCCINATE) : 6 MG / 0.5 ML · DIN 02212188 · GLAXOSMITHKLINE INC
Health Canada status: MARKETED
What is IMITREX?
IMITREX 6 MG / 0.5 ML contains SUMATRIPTAN (SUMATRIPTAN SUCCINATE) : 6 MG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02212188, held by GLAXOSMITHKLINE INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 11-Aug-2003. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is IMITREX used for?
IMITREX DF (sumatriptan succinate) and IMITREX (sumatriptan succinate/sumatriptan hemisulphate) are indicated for the acute treatment of migraine attacks with or without aura. IMITREX DF and IMITREX are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, basilar, or ophthalmoplegic migraine.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02212188 |
|---|---|
| Brand name | IMITREX |
| Generic / active ingredient | SUMATRIPTAN (SUMATRIPTAN SUCCINATE) : 6 MG / 0.5 ML |
| Manufacturer | GLAXOSMITHKLINE INC |
| Strength | 6 MG / 0.5 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | N02CC01 SUMATRIPTAN |
| AHFS class | 28:32.28 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Aug-2003 |
| Original market date | 1999-08-30 00:00:00 |
How is it stored and handled?
null
How is it supplied?
IMITREX DF Tablets are available as pink 100 mg, or white 50 mg film-coated tablets in blister packs containing 6 tablets. IMITREX Injection (6 mg; total volume = 0.5 mL) is available in pre-filled syringes placed in a tamper-evident carrying/disposal case. Two pre-filled syringes plus an IMITREX STATdose Pen autoinjector are packed in an IMITREX STATdose System autoinjector kit. A refill pack is available containing 2 pre-filled syringes in a carton. IMITREX Nasal Spray 5 mg and 20 mg are each supplied in boxes of 2 nasal spray devices (1 X 2 devices). Each unit dose spray supplies 5 and 20 mg, respectively.
Is SUMATRIPTAN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N02CC01 SUMATRIPTAN. 32 of 80 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-SUMATRIPTAN | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02268396 |
| APO-SUMATRIPTAN | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02268388 |
| IMITREX | 20 MG | SPRAY | GLAXOSMITHKLINE INC | MARKETED | DIN 02230420 |
| IMITREX | 5 MG | SPRAY | GLAXOSMITHKLINE INC | MARKETED | DIN 02230418 |
| IMITREX DF - TAB 100MG | 100 MG | TABLET | GLAXOSMITHKLINE INC | MARKETED | DIN 02212161 |
| JAMP SUMATRIPTAN | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02545365 |
| JAMP SUMATRIPTAN | 25 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02545349 |
| JAMP SUMATRIPTAN | 50 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02545357 |
| JAMP SUMATRIPTAN DF | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02545314 |
| JAMP SUMATRIPTAN DF | 25 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02545292 |
Who else supplies SUMATRIPTAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SUMATRIPTAN appears in 269 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.